Advice
in the absence of a submission from the holder of the marketing authorisation:
belimumab (Benlysta®) is not recommended for use within NHSScotland.
Indication under review: In combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice623KB (PDF)
Medicine details
- Medicine name:
- belimumab (Benlysta)
- SMC ID:
- SMC2483
- Indication:
In combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 11 April 2022